Barclays analyst Etzer Darout raised the firm’s price target on Oruka Therapeutics (ORKA) to $160 from $78 and keeps an Overweight rating on the shares. The firm upped the price target after Oruka announced interim results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA: